Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 106
- Registration Number
- NCT00027703
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Ottawa Regional Cancer Centre
- Target Recruit Count
- 30
- Registration Number
- NCT00002608
- Locations
- 🇨🇦
Ottawa Regional Cancer Centre at Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
- Conditions
- Childhood Mixed Cellularity Classical Hodgkin LymphomaStage I Childhood Hodgkin LymphomaStage IV Childhood Hodgkin LymphomaChildhood Lymphocyte-Depleted Classical Hodgkin LymphomaChildhood Nodular Lymphocyte Predominant Hodgkin LymphomaStage II Childhood Hodgkin LymphomaChildhood Nodular Sclerosis Classical Hodgkin LymphomaStage III Childhood Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1734
- Registration Number
- NCT00025259
- Locations
- 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 521
- Registration Number
- NCT00005047
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States
🇺🇸Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport, Louisiana, United States
🇺🇸William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States
Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-05
- Target Recruit Count
- 686
- Registration Number
- NCT00039338
- Locations
- 🇦🇹
Karl-Franzens-University Graz, Graz, Austria
🇮🇹Ospedale Mauriziano Umberto I, Torino, Italy
🇧🇪Centre Hospitalier Regional de la Citadelle, Liege, Belgium
Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 259
- Registration Number
- NCT00012220
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
🇺🇸CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸Veterans Affairs Medical Center - Asheville, Asheville, North Carolina, United States
Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00006260
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT00005819
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-06-10
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT00028665
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 140
- Registration Number
- NCT00002882
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.